Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals

T. L. Hall, Lisa A Tell, S. E. Wetzlich, J. D. Mccormick, L. W. Fowler, Nicola Pusterla

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5mg/kg body weight; n=6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6mg/kg body weight; n=6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC 0→∝ (86.4±8.5 and 91±22h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82±1.00 and 5.55±0.81h for i.v. and s.c., respectively), C max(obs) (13±1.9μg/mL s.c.), T max(obs) (0.75±0.4h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC 0→∝ (139.53±22.63h·μg/mL), terminal elimination half-life (39.7±14.7), C max(obs) (2.52±0.35μg/mL) and t max(obs) (11.33±1.63h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.

Original languageEnglish (US)
Pages (from-to)403-409
Number of pages7
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume34
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

ceftiofur
foals
pharmacokinetics
Pharmacokinetics
Acids
acids
subcutaneous injection
half life
Area Under Curve
Half-Life
Body Weight
metabolites
drugs
cephalosporins
body weight
Cephalosporins
intravenous injection
Pharmaceutical Preparations
Intravenous Administration
high performance liquid chromatography

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals. / Hall, T. L.; Tell, Lisa A; Wetzlich, S. E.; Mccormick, J. D.; Fowler, L. W.; Pusterla, Nicola.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 34, No. 4, 08.2011, p. 403-409.

Research output: Contribution to journalArticle

@article{526fdbec63c94f9d9b0b9bdfaacae6a5,
title = "Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals",
abstract = "Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5mg/kg body weight; n=6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6mg/kg body weight; n=6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC 0→∝ (86.4±8.5 and 91±22h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82±1.00 and 5.55±0.81h for i.v. and s.c., respectively), C max(obs) (13±1.9μg/mL s.c.), T max(obs) (0.75±0.4h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC 0→∝ (139.53±22.63h·μg/mL), terminal elimination half-life (39.7±14.7), C max(obs) (2.52±0.35μg/mL) and t max(obs) (11.33±1.63h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.",
author = "Hall, {T. L.} and Tell, {Lisa A} and Wetzlich, {S. E.} and Mccormick, {J. D.} and Fowler, {L. W.} and Nicola Pusterla",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2885.2010.01252.x",
language = "English (US)",
volume = "34",
pages = "403--409",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals

AU - Hall, T. L.

AU - Tell, Lisa A

AU - Wetzlich, S. E.

AU - Mccormick, J. D.

AU - Fowler, L. W.

AU - Pusterla, Nicola

PY - 2011/8

Y1 - 2011/8

N2 - Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5mg/kg body weight; n=6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6mg/kg body weight; n=6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC 0→∝ (86.4±8.5 and 91±22h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82±1.00 and 5.55±0.81h for i.v. and s.c., respectively), C max(obs) (13±1.9μg/mL s.c.), T max(obs) (0.75±0.4h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC 0→∝ (139.53±22.63h·μg/mL), terminal elimination half-life (39.7±14.7), C max(obs) (2.52±0.35μg/mL) and t max(obs) (11.33±1.63h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.

AB - Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5mg/kg body weight; n=6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6mg/kg body weight; n=6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC 0→∝ (86.4±8.5 and 91±22h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82±1.00 and 5.55±0.81h for i.v. and s.c., respectively), C max(obs) (13±1.9μg/mL s.c.), T max(obs) (0.75±0.4h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC 0→∝ (139.53±22.63h·μg/mL), terminal elimination half-life (39.7±14.7), C max(obs) (2.52±0.35μg/mL) and t max(obs) (11.33±1.63h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.

UR - http://www.scopus.com/inward/record.url?scp=79960075738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960075738&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2885.2010.01252.x

DO - 10.1111/j.1365-2885.2010.01252.x

M3 - Article

VL - 34

SP - 403

EP - 409

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 4

ER -